Cantor Fitzgerald Thinks Optinose Inc’s Stock is Going to Recover


Cantor Fitzgerald analyst Brandon Folkes maintained a Buy rating on Optinose Inc (OPTN) today and set a price target of $27. The company’s shares closed yesterday at $9.41, close to its 52-week low of $5.66.

Folkes said:

“. Post a day of meetings with CEO Peter Miller and CFO Keith Goldan, we are reiterating our OW rating and $27 12-month PT for OPTN. We continue to have confidence in our peak sales estimates for Xhance, and post the changes in the co-pay program, scripts have trended well. For 2019, we believe increased access, better affordability, the sales force expansion and increased awareness of the good efficacy data should continue to drive script growth throughout the year and beyond. We continue to take a conservative approach to Xhance revenue in 2019, and on the NDR, management did not comment on whether it thinks consensus estimates for 2019 are reasonable.”

According to TipRanks.com, Folkes is a 3-star analyst with an average return of 2.0% and a 37.8% success rate. Folkes covers the Healthcare sector, focusing on stocks such as Opiant Pharmaceuticals Inc, Eagle Pharmaceuticals Inc, and Collegium Pharmaceutical.

The word on The Street in general, suggests a Strong Buy analyst consensus rating for Optinose Inc with a $24.33 average price target, representing a 158.6% upside. In a report issued on March 7, RBC Capital also maintained a Buy rating on the stock with a $25 price target.

See today’s analyst top recommended stocks >>

The company has a one-year high of $30 and a one-year low of $5.66. Currently, Optinose Inc has an average volume of 186.2K.

Based on the recent corporate insider activity of 11 insiders, corporate insider sentiment is negative on the stock.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

OptiNose, Inc. is a pharmaceutical company, which engages in the development and commercialization of products for patients treated by ear, nose, throat, and allergy specialists. Its products include the XHANCE and ONZETRA Xsail. The company was founded by Per Gisle Djupesland and Helena Kyttari Djupesland in May 2010 and is headquartered in Yardley, PA.

Stay Ahead of Everyone Else

Get The Latest Stock News Alerts